CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer.
Fracassi G, Lorenzin F, Orlando F, Gioia U, D'Amato G, Casaramona AS, Cantore T, Prandi D, Santer FR, Klocker H, d'Adda di Fagagna F, Mateo J, Demichelis F.
Fracassi G, et al.
J Clin Invest. 2024 Dec 24:e179393. doi: 10.1172/JCI179393. Online ahead of print.
J Clin Invest. 2024.
PMID: 39718835
Free article.